A split-face, randomized controlled trial of efficacy and tolerability of fractional CO2 laser combined with autologous platelet rich plasma versus fractional CO2 laser alone in the treatment of atrophic acne scars: a pilot study

Phase 4

• Conditions: Symmetrical atrophic acne scars on both sides of the face; fractional CO2 laser, platelet-rich plasma, PRP, ablative carbon dioxide fractional laser atrophic acne scars

• Registration Number: TCTR20210702005
• Lead Sponsor: Astraco Medical Networks Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-02
• Study Completion: 2021-12-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Subjects age 18-50 years old who have symmetrical atrophic acne scars on both sides of the face with mild to severe severity of acne scars.
2. Duration of acne scar from 6 months to 10 years.
3. Subjects are willing to comply with study protocol and sign informed consent.

Exclusion Criteria

1. Subjects with moderate to severe acne vulgaris (IGA3-4) or currently have active and uncontrolled acne vulgaris.
2. Female subjects who are currently in pregnancy or breastfeeding.
3. Subjects who have rash, infection or other dermatologic diseases on face.
4. Dermatologic procedural treatments within previous 3 months before study enrollment.
5. Subjects with active herpes infection, bleeding diathesis, cancer, HIV or HBV infection.
6. Subjects who have taken isotretinoin within previous 6 months.
7. Subjects who are currently on antiplatelet or anticoagulant drugs.
8. Subjects woth predisposition to keloid formation.
9. Subjects who cannot comply with the study protocol.

Study & Design

• Study Type: Interventional
• Study Design: Not specified